Skip to content Skip to footer
Subscribe Now
INSIGHTS+

Know Your Investor: Google Ventures (October’25 Edition) 

Shots: Welcome to the October edition of Know Your Investor, spotlighting leading investors shaping the future of healthcare and life sciences This month, we feature Google Ventures (GV), the venture capital arm of Alphabet. GV actively invests across seed to growth-stage companies, spanning sectors such as software, internet, healthcare, life sciences, and artificial intelligence For…
October 16, 2025

Read more

NEWS

Areteia Therapeutics Reports P-III (EXHALE-4) Trial Data of Dexpramipexole to Treat Eosinophilic Asthma

Shots:Areteia Therapeutics has reported P-III (EXHALE-4) trial data assessing dexpramipexole (75 or 150mg, PO, BID) vs PBO as an add-on therapy to treat pts (n=600; ≥12yrs.) with inadequately controlled moderate-to-severe asthma & blood AEC ≥300 cells/μLTrial showed that 150mg improved lung function over Wks. 20 & 24 (1EP), as measured by pre-BD FEV1…
September 17, 2025

Read more

Know Your Investor: Google Ventures
INSIGHTS+

Know Your Investor: Google Ventures

Shots: An investment arm of Alphabet Inc., Google Ventures Management Company colossally in seed stage companies, in diverse fields ranging from software and internet to healthcare, life sciences, and artificial intelligence among others Since 2016, GV has shifted its focus from seed-stage companies to evolved companies. With over $8B worth of assets under the management…
December 27, 2023

Read more